NeoStem Inc. (AMEX: NBS)

Dear Reader,

The scientific developments coming as a result of adult stem cell research are emerging at warp speed.  Month after month, new breakthroughs and developments realize the potential that stem cell-related treatments and therapies can and will offer.  As the editors of this publication, we have long been infatuated with stem cells… both as a vehicle to change our lives and as an investment vehicle. There’s no denying the enthusiasm for either.

So, when we were presented with the opportunity to bring to your attention an intriguing stem cell-related company being traded on the prestigious American Stock Exchange we were enthusiastic.  NeoStem's proprietary technologies empower health-conscious consumers to help protect their future health by storing their own stem cells - providing an accessible supply of healthy, genetically matched stem cells.  

After reading just a few paragraphs below you’ll see both the opportunities with NeoStem, Inc. (AMEX:NBS) and in stem cells at large.  Then watch the news for stem cell headlines.  Better yet, just do a Google search for “Stem Cell Breakthroughs” and see what comes up.  It’s truly breathtaking stuff.  
>>>Spacer>>>

* * Breaking News from NeoStem * *

NEW YORK—August 17, 2007 -- NeoStem, Inc. (AMEX: NBS), the first company to specialize in the collection, processing and storage of stem cells from healthy adults for personal use in times of critical medical need, announced today that it has filed a far-reaching patent application that initiates the process of safeguarding the Company’s proprietary procedures for collecting, storing and developing potential biotherapies from adult stem cells derived from a patient’s own body. The application encompasses several groundbreaking concepts that include next generation biomedical services such as bio-insurance and the formulation of designer stem cell-related therapies for healthy individuals interested in mitigating potential health conditions in the future.

NeoStem’s proprietary technology positions the company at the forefront of a bold new shift in the medical industry where the patient’s own body would provide the materials, such as adult stem cells, necessary to formulate therapies that have, until recently, been provided by pharmaceutical companies in the form of synthetic, chemically engineered drugs.

"We believe NeoStem is positioned to take a leadership role in the emerging stem cell therapeutic market by fractionating the cells for the treatment of different diseases in what many medical doctors and scientists believe to be the next great revolution in medicine," said Robin Smith, M.D., Chairman and Chief Executive Officer of NeoStem. "We believe we are at the threshold of stem cells being a mainstream therapeutic that will dramatically change how medicine is practiced in the future. NeoStem is firmly committed to protect and continue to build a robust portfolio of pending patents as a means to securing long-term value for our shareholders."

NeoStem’s first-to-market competitive advantage uniquely positions the Company to capitalize on the hundreds of adult stem cell-based clinical therapy trials currently underway. As these stem cell-based therapies become available, NeoStem clients will be among the first to benefit from the life saving progress that has already been made for such debilitating conditions as cancer, heart disease, multiple sclerosis, lupus, and many others. 

"It is important for investors to understand that we believe that our proprietary technology positions us above and beyond the processes currently being employed by cord blood banks, which simply inject the entire spectrum of stem cells without regard to the specific disease target," said Denis Rodgerson, Ph.D., Director of Stem Cell Science of NeoStem. "We believe that the NeoStem service offering will prove to be heads and shoulders above any other stem cell services company."

The NeoStem process begins when a physician or health industry professional identifies a individual who could benefit from having their stem cells collected and banked. Candidates for bio-insurance include a broad range of adults, including health conscious individuals, someone with genetic risk factors, or patients in early-disease states. Once the physician has extracted the patient’s stem cells from peripheral blood (through a non-invasive, easy-to-administer process) the stem cells are sent to a NeoStem facility to be cryopreserved, stored and characterized. If the need arises in the future, NeoStem clients may benefit from prompt access to therapeutically useful, genetically matched adult stem cells. NeoStem generates revenues from every stage of that process.

About NeoStem, Inc. 
NeoStem is a biotechnology services company enhancing the delivery of adult stem cell therapeutics to health-conscious consumers. The Company is developing a nationwide network of adult stem cell collection centers, enabling people to donate and store their own stem cells with NeoStem for personal use years or decades later in times of critical medical need. 

The proprietary NeoStem technologies empower health-conscious consumers to help protect their future health by undergoing treatment with their own stem-cells - providing an accessible supply of healthy, genetically matched stem cells for use in the eventuality of illness. 

Currently underway are hundreds of stem cell-based research programs and clinical trials investigating the use of these non-controversial adult stem cells, such as those collected from donors under NeoStem's methods. As the nation's population ages and encounters serious age-related and congenital health issues, NeoStem has positioned itself as a leader in the fast-growing national trend toward personal "bio-insurance." 

The Company's non-capital intensive business plan is a service model that is completely scalable, thus minimizing risk levels ordinarily related to most long-term biopharmaceutical research and development. Under its strategic business plan, NeoStem has begun opening a nationwide network of adult stem cell collection facilities. Its stem cell collection systems will be located in existing physician offices and medical facilities, where the procedures and care can be administered by trusted personal doctors and medical professionals. 
For more information, please visit: www.neostem.com. 

For other information and resources about the Company, visit www.CFSG1.com or www.trilogy-capital.com/tcp/neostem/quote.html. 

Forward-Looking Statements 
Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the ability of NeoStem, Inc. ("the Company") to develop the adult stem cell business, the future of regenerative medicine and the role of adult stem cells in that future, the future use of adult stem cells as a treatment option and the potential revenue growth of the Company's business. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. The Company's ability to enter the adult stem cell arena, its success in such arena  and future operating results are dependent upon many factors, including but not limited to (i) the Company's ability to obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) the Company's ability to build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; (iv) scientific and medical developments beyond the Company's control; (v) the Company's inability to obtain appropriate state licenses or any other adverse effect or limitations caused by government regulation of the business; (vi) whether any of the Company’s current or future patent applications result in issued patents;   and (vii) other risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission which are available for review at www.sec.gov under "Search for Company Filings."

Pursuant to an October 1, 2006 agreement, Consulting For Strategic Growth I, Ltd. ("CFSG1") provides the Company with consulting, business advisory, investor relations, public relations and corporate development services, for which CFSG1 receives a fixed monthly fee for the duration of the agreement and received shares of NeoStem's common stock. Independent of CFSG1's receipt of cash or other compensation from the Company, CFSG1 may choose to purchase the common stock of the Company and thereafter sell those shares at any time it deems appropriate to do so. For more information, please visit www.cfsg1.com. 

NeoStem, Inc.
Robin Smith, Chief Executive Officer, 212-584-4180
rsmith@neostem.com
www.neostem.com
or
Consulting for Strategic Growth 1
Stanley Wunderlich/Daniel Stepanek, 800-625-2236
Fax: 212-337-8089
http://www.cfsg1.com
or
Financial Communications
Trilogy Capital Partners
Ryon Harms, 800-592-6067
ryon@trilogy-capital.com 
>>>Spacer>>>

About NeoStem

NeoStem, Inc. ("NeoStem" "Neo" "NBS") is a next generation biotechnology services company enhancing the delivery of adult stem cell therapeutics to health-conscious consumers. NBS is developing a nationwide network of adult stem cell collection centers, enabling people to donate and store their own stem cells for personal use years or decades later in times of critical medical need.

The proprietary NeoStem technologies empower health-conscious consumers to help protect their future health by storing their own stem cells - providing an accessible supply of healthy, genetically matched stem cells.

Independent market researchers estimate that stem cell therapy sales in the United States are projected to reach more than $700 million by 2010 and $8.5 billion by 2016, based on therapies being investigated. Currently underway are nearly 200 research programs specifically involving the use of autologous adult stem cells – those donated by individuals for their personal use. As the nation’s population ages and encounters serious age-related and congenital health issues, NeoStem has positioned itself as a leader in the fast-growing national trend toward personal “bio-insurance.”

Prospective NeoStem customers include: health conscious individuals, persons with genetic risk factors, patients in pre-disease states or early disease states, individuals with job-related risk factors such as radiation exposure, and others. Adult stem cell therapies being investigated include potential treatments of serious injury and illness, such as cancer, heart disease, spinal cord injury, as well as age-related conditions such as Alzheimer’s and macular degeneration, a leading cause of blindness.

Unlike controversial embryonic stem cell technologies, adult stem cells have a 40-year history of successful, real world therapeutic application. Life saving progress in this field has already been made for the treatment of heart disease, lupus, multiple sclerosis, cancer, diabetes and many other critical health problems - currently comprising a patient population of more than 50 million patients in the United States alone.

Neo's service model does not take years of development before generating revenues and thus minimizes the risk related to most long-term biopharmaceutical research and development. Under Management’s strategic initiatives, NeoStem has already begun opening a nationwide network of adult stem cell collection centers, and NeoStem will process and store these stem cells. The collection technologies and processes will be located in existing physician offices and medical facilities, where the procedures can be administered by trusted personal physicians and medical professionals.

...overview...

• NeoStem pioneers the pre-disease collection, processing and storage of stem cells from adult donors 
• NBS is well positioned to be the leading provider of autologous adult stem cells for therapeutic use in regenerative medicine
• NeoStem provides a process that is safe and non-invasive
• NBS uses proprietary technology for the mobilization, processing and multiple use storage
• NeoStem technology with re-infusion does not have the risk of rejection or graft vs. host disease
• NBS IS NOT caught in political policy, debate or religious controversy

NeoStem’s private paying targeted clients 

• Health conscious individuals interested in potential future use of ASC’s in anti-aging and regenerative medicine
• Individuals with disease predisposition because of genetic or current medical risk factors 
• Individuals with disease conditions that are treatable with ASCs.
• BioInsurance policy for the future in the event of a life threatening illness that may be treatable with ASCs 

NBS will also generate revenues through research grants such as NIH, Foundation and Philanthropic programs.

NeoStem generates revenue from:

• Collections at company owned sites
• Processing and Storage (recurring revenue)
• Utilization Fee (when cells are used)

NeoStem has two pending U.S. patent applications describing key aspects of our process. These applications address: the process by which NeoStem prepares and stores stem cells collected from the peripheral blood by an apheresis process. the use of stored stem cell to form the basis for medical information that will provide statistics for etiology of disease.
>>>space>>>

* * * What is a Stem Cell ? * * *

A stem cell is a special kind of cell that has the unique capacity to replicate or “self-renew” over a long period of time, often throughout the life of an organism. Under the right conditions or given the right signals, stem cells have the potential to develop into the specialized cells that make up the tissues and organs of the body, such as heart cells, nerve cells and even inner ear hair cells.

Adult stem cells are undifferentiated or unspecialized cells that are found embedded in specialized tissue. Adult stem cells are capable of making identical copies of themselves for the lifetime of the organism. They can form themselves into specialized cells that match the tissues from which they originate, thereby regenerating from within. For example, stem cells taken from bone marrow can give rise to new blood cells even after they are transplanted elsewhere. There is evidence that adult stem cells have even greater potential than this and that they may be used to generate many more cell types than just the cells of the organ from which they were removed. 

The NeoStem Adult Stem Cell Collection Process

• Registration 
• History, Physical and Lab Work (Hospital or Referring Physician) 
• Comprehensive Health Survey (NeoStem)
• Mobilization (Hospital or Referring Physician)
• Collection – Apheresis (Hospital or NeoStem)
• Cell Processing (NeoStem) 
• Cryogenic preservation (NeoStem) 
• Comprehensive Stem Cell Report (NeoStem)

The prepared cells are cooled in a controlled-rate freezer and transferred to a liquid nitrogen tanks for long-term storage

The Adult Stem Cell Market

By 2010, it is estimated that 39% of the U.S. population (over 110 mm people) will be 45 years of age or older. There is an anticipated rapid increase in age associated diseases and “Bio-Insurance” - banking someones own stem cells for future use to treat a disease - will become BIG BUSINESS.

Other Recent News From NeoStem

Press Release Source: NeoStem, Inc.
Tuesday August 14, 4:23 pm ET

NEW YORK--(BUSINESS WIRE)--NeoStem, Inc. (AMEX:NBS - News), the first company to specialize in the collection, processing and long term storage of stem cells from healthy adults for personal use in times of critical medical need, today announced completion of its second closing of its public offering generating $1 million in gross proceeds. Together with the gross proceeds of the first closing of the public offering on August 9, 2007, the Company has raised an aggregate of approximately $6.3 million.

The public financing was comprised of 1,270,000 units with each unit consisting of one share of common stock and one-half of a five year Class A warrant to purchase one-half a share of common stock at a price of $6 per share.

You May View the Entire news Release HERE

NEW YORK--(BUSINESS WIRE)--NeoStem, Inc. (OTCBB:NEOI - News), the first company to specialize in the collection, processing and long term storage of stem cells from healthy adults for personal use in times of critical medical need, today announces its common stock and units have been approved to be listed on the American Stock Exchange under the ticker symbols--NBS and NBS.U--and will start trading August 9, 2007. The listing followed the completion of a public-offering in excess of $5 million and a one-for-ten reverse stock split.

The listing on the American Stock Exchange is consistent with the Company's strategic mission to attract institutional investors and to provide long-term value for its shareholders.

"We are extremely proud of our recent achievements and of surpassing yet another milestone for the benefit of our shareholders," said Robin Smith, M.D., Chairman and Chief Executive Officer of NeoStem. "It is an honor to be listed on the American Stock Exchange and to enjoy all the benefits of its long and storied history. We believe these recent developments will be major catalysts as we move forward into a position of leadership in the burgeoning market for stem cell therapies and services."

The closing of this offering is the latest validation of NeoStem's high-growth business model focused on developing next generation services and therapies that have the potential to help millions of health-conscious individuals. The total offering comprises units at a price of $5 per unit. Each unit consists of one share of common stock and one-half a Class A warrant to purchase one-half a share of common stock. Thus, 1,000 units consist of 1,000 shares and warrants to purchase 500 shares of common stock.

You May View the Entire news Release HERE

Bethlehem, PA, May 16, 2007 --(PR.com)-- Azani Medical Spa, located in Bethlehem Pennsylvania under the direction of founder and Medical Director Monica Carezani-Gavin, MD, has announced an agreement with the New York City-based biotechnology services company NeoStem, Inc. to become the first facility in Eastern Pennsylvania and Western New Jersey to offer adult stem cell collection and long-term storage services to the public.

NeoStem specializes in the collection, processing and long-term storage of adult stem cells for autologous use, meaning the collection of one’s own stem cells for one’s own use for possible future therapeutic applications. NeoStem’s technology provides its patients with adult stem cell collection and banking services via a two-step process where a patient’s stem cells are mobilized (allowing the stem cells to pass from the person’s bone marrow into the peripheral blood), followed by a process called apheresis (a safe, painless and non-invasive procedure similar to donating blood) which separates and collects the stem cells from the patient’s blood. The patient’s cells are then processed and cryo-preserved at a NeoStem processing and storage facility where the cells are available should a patient need them in the future.

“Science shows us that stem cells from an individual’s own body can be used to change the course of certain chronic diseases such as heart disease, lupus, multiple myeloma, multiple sclerosis, and leukemia as well as rheumatoid arthritis and even chronic wounds,” commented Dr. Gavin. “We believe the people of Eastern Pennsylvania and Western New Jersey will take full advantage of having the advanced adult stem cell technologies offered by NeoStem right in their own backyard.”

Adult stem cells are becoming an important element in regenerative medicine and treatments for numerous diseases. They have already provided helpful treatment in certain blood cancers, cases of heart disease, autoimmune disease such as lupus, radiation exposure and wound healing. Over 600 adult stem cell clinical trials are underway and many more clinical applications using adult stem cells will develop in the future.

You May View the Entire news Release HERE
a

Dr. Robin L. Smith - Chairman and CEO of NeoStem

Prior to being appointed Chairman of the Board of Directors and Chief Executive Officer of NeoStem, Inc., Dr. Robin L. Smith has acted as a senior advisor and investor to both publicly traded and privately held companies including but not limited to China Biopharmaceutical Holdings, Phase III Medical, the Madelin Fund, HC Innovations, Inc., Navstar Media Holdings, Strike Force and Health Quest, where she has played a significant role in restructuring and or growing companies.  Additionally, she has advised and evaluated companies in health care, media and emerging technologies for multiple investment banks and funds including Capital Growth Financial.  Dr. Robin Smith is on the Board of Directors of Talon Air and Biomega, two privately held companies and is also a a director of the Chemotherapy Foundation and the New York University Hospital as well as Co-Chairman of the Board for the New York University Hospital for Joint Diseases.

Financial Highlights For NeoStem

• NeoStem has the first to market advantage in the collection and storage of stem cells extracted from adults
• NeoStem represents a high growth opportunity in a large growing market
• NeoStem is well positioned with industry leaders and academic institutions
• NeoStem has an attractive valuation compared to other stem cell related companies

To Contact NeoStem

---

***The Bull is Running. ***
There may never be a better time to feature YOUR company
to over 1 MILLION investors.

To learn more about our programs email us directly at info@stockupticks.com

Disclaimer: StockUpTicks.com is a property of Market Pathways Financial Relations Incorporated (MP).  The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. Past performance is no guarantee of future results. This report is a paid advertisement and is for information purposes only and should not be used as the basis for any investment decision.  MP has been paid fifteen thousand dollars by Trilogy Capital Partners for preparation and distribution of this report and other advertising services over a ninety day period. This constitutes a conflict of interest as to MP’s ability to remain objective in its communication regarding the subject company.  Write or call MP for detailed disclosure as required by Rule 17b of the Securities Act of 1933/1934 - Market Pathways 17595 Harvard Ave., Suite C519 Irvine, CA  92614.  MP is not an investment advisor and this report is not investment advice. This information is neither a solicitation to buy nor an offer to sell securities but is a paid advertisement.  Information contained herein contains forward-looking statements and is subject to significant risks and uncertainties, which will affect the results.  The opinions contained herein reflect our current judgment and are subject to change without notice. MP and/or its affiliates, associates and employees from time to time may have either a long or short position in securities mentioned.  Information contained herein may not be reproduced in whole or in part without the express written consent of Market Pathways Financial Relations Incorporated.